Literature DB >> 15912090

Current status of clinical islet transplantation.

Olle Korsgren1, B Nilsson, C Berne, M Felldin, A Foss, R Kallen, T Lundgren, K Salmela, A Tibell, G Tufveson.   

Abstract

Islet transplantation is currently being explored as a treatment for patients with type 1 diabetes. At present, the number of patients becoming insulin-independent is rapidly increasing world-wide applying the transplantation protocol originally described by the group in Edmonton. A hallmark in this procedure is repeated infusions of islets obtained from 2 to 4 donors until normoglycemia is achieved. In order to establish islet transplantation as a widely accepted treatment modality, and make tolerance induction regimes applicable, it is essential that the donor:recipient ratio is brought down to 1:1. A conceivable strategy to achieve this goal in clinical islet transplantation is discussed.

Entities:  

Mesh:

Year:  2005        PMID: 15912090     DOI: 10.1097/01.tp.0000157273.60147.7c

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  33 in total

Review 1.  Imaging the islet graft by positron emission tomography.

Authors:  Olof Eriksson; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-20       Impact factor: 9.236

2.  A replacement for islet equivalents with improved reliability and validity.

Authors:  Han-Hung Huang; Karthik Ramachandran; Lisa Stehno-Bittel
Journal:  Acta Diabetol       Date:  2013-10       Impact factor: 4.280

3.  Physiologic Doses of Bilirubin Contribute to Tolerance of Islet Transplants by Suppressing the Innate Immune Response.

Authors:  Christopher A Adin; Zachary C VanGundy; Tracey L Papenfuss; Feng Xu; Mostafa Ghanem; Jonathan Lakey; Gregg A Hadley
Journal:  Cell Transplant       Date:  2016-07-07       Impact factor: 4.064

4.  Predicting the outcome of islet isolation in large mammals.

Authors:  T Hubert; V Gmyr; M C Vantyghem; J Kerr-Conte; F Pattou
Journal:  Diabetologia       Date:  2008-11-21       Impact factor: 10.122

5.  The synthetic liver X receptor agonist GW3965 reduces tissue factor production and inflammatory responses in human islets in vitro.

Authors:  H Scholz; T Lund; M K Dahle; J L Collins; O Korsgren; J E Wang; A Foss
Journal:  Diabetologia       Date:  2009-05-05       Impact factor: 10.122

Review 6.  Pig-to-Primate Islet Xenotransplantation: Past, Present, and Future.

Authors:  Zhengzhao Liu; Wenbao Hu; Tian He; Yifan Dai; Hidetaka Hara; Rita Bottino; David K C Cooper; Zhiming Cai; Lisha Mou
Journal:  Cell Transplant       Date:  2017-02-03       Impact factor: 4.064

7.  The ATP/DNA ratio is a better indicator of islet cell viability than the ADP/ATP ratio.

Authors:  T M Suszynski; G M Wildey; E J Falde; G W Cline; K Stewart Maynard; N Ko; J Sotiris; A Naji; B J Hering; K K Papas
Journal:  Transplant Proc       Date:  2008-03       Impact factor: 1.066

8.  Islet cell transplantation.

Authors:  Brian Funaki
Journal:  Semin Intervent Radiol       Date:  2006-09       Impact factor: 1.513

9.  Localized immune tolerance from FasL-functionalized PLG scaffolds.

Authors:  Michael Skoumal; Kyle B Woodward; Hong Zhao; Feng Wang; Esma S Yolcu; Ryan M Pearson; Kevin R Hughes; Andrés J García; Lonnie D Shea; Haval Shirwan
Journal:  Biomaterials       Date:  2018-11-13       Impact factor: 12.479

10.  Anti-inflammatory thalidomide improves islet grafts survival and functions in a xenogenic environment.

Authors:  Chunguang Chen; Carina Kuehn; Reinhard G Bretzel; Thomas Linn
Journal:  PLoS One       Date:  2009-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.